Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Chemokine gets US patent for novel cancer drug



20 June, 2005: Biotechnology major Chemokine Therapeutics Corporation has received US patent for use of its anti-cancer compound, CTCE-9908. The compound is being designed to address cancer, cardiovascular and other infectious diseases.

"With the issue of the patent (No 6,875,738), we are expanding our proprietary position in peptide-based drug development, a new pharmaceutical drug class with the potential to treat a number of diseases and disorders," Chemokine Therapeutics President and Chief Executive Officer Dr Hassan Salari said.

"I believe we are among the first companies to develop synthetic chemokines that have been shown to be functional in living systems and safe in our initial studies in humans," he said in a statement released to the media.

Inhibition of blood vessel growth to tumours by novel blockade CTCE-9908 represents an exciting new generation of drugs being developed that promise more targeted therapies to treat the underlying cancer while keeping healthy cells intact, the company claimed in the patent request.

It also claims that the compound treats cancer and inhibiting angiogenesis (blood vessel growth) by administration of an antagonist that blocks a chemokine receptor known as CXCR4.

Chemokines are a class of cytokines, a group of soluble proteins, which signal biological responses that play a critical role in the immune system.

Blockage of CXCR4 reduces growth of tumours by reducing blood vessel growth (anti-angiogenesis) that carries vital nutrients to a tumour. The company has completed a Phase I, dose-escalation clinical trial using CTCE-9908 in United Kingdom to assess its safety in healthy volunteers.

The clinical trials exhibited no adverse effects, the company claimed.

Many of these biological signals are necessary for fighting infection, tissue repair and regeneration. Chemokines also play a major role in cancer and autoimmune disorders that contribute to survival and growth of abnormal cells.

Cancer researchers have demonstrated that high CXCR4 expression in cancer cells is correlated to tumour progression, high metastasis rate and low survival rate. 




All cancer headlines

Drug for advanced colorectal cancer gets marketing nod in Canada
18 September,2005

Advanced prostate cancer therapy Provenge seeks marketing nod in US
18 September,2005

New kidney cancer drug seeks EU nod
13 September,2005

Breast cancer drug Aromasin approved in Europe: Pfizer  
15 Sep, 2005

Lung cancer vaccine trials promising: Introgen 
13 September,2005 

Rituxan, cancer drug can treat rheumatoid arthritis
2 September, 2005

Novartisí drug for breast cancer recurrence to be given priority review in US
31 August, 2005

New cancer combo therapy results positive: OXiGENE
25 August, 2005 

Cell Therapeutics to seek approval for lung cancer therapy in US and Europe
25 August, 2005

Aspirin stops colon cancer, but may trigger bleeding
24 August, 2005

Skin disease drug turns into anti-tumor therapy for cancer
22 August, 2005

"Breast cancer chances higher due to fried chips"
22 August, 2005

Pfizer files NDA for Sutent in US
13th August,2005

Alcohol linked cancers: Acetaldehyde in spot light
10 August, 2005

Chemokine gets US patent for novel cancer drug
20 June, 2005

Prohibitive costs mar cancer therapy
15 July, 2005

Viruses may help cure cancer by killing cancer cells
CALGARY, Alberta, June 28

Cervical Cancer detector may improve on Pap Smears
CHERRY HILL, N.J., June 28 

Novartis has better breast cancer treatment
Toronto, Ontario, April 11, 2005

Roche, Novartis lead on novel cancer therapies
23 July, 2005

Pfizer's investigational drug reduces tumor growth
14 May, 2005

   Pharma Home


Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us